Shares of Emcure Pharma surges over 31 percent in debut trade
New Delhi: Shares of Emcure Pharmaceuticals Ltd made a debut on Wednesday as they listed with a significant premium of over 31 percent against their issue price of Rs 1,008.
The stock opened trading at Rs 1,325.05, up 31.45 per cent on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), marking a strong initial surge.
Later, the company's stock zoomed 37.30 per cent to Rs 1,384 on BSE and 37.40 per cent to Rs 1,385 on NSE.
According to PTI report, the company's market valuation stood at Rs 25,546.24 crore.
The initial public offering (IPO) of Bain Capital-backed Emcure Pharmaceuticals received 67.87 times subscription on the final day of the offer on Friday amid encouraging participation from institutional buyers.
The initial share sale had a price band of Rs 960-1,008 per share.
The IPO had a fresh issuance of equity shares worth Rs 800 crore and an offer of sale (OFS) of 1.14 crore shares worth Rs 1,152 crore at the upper end of the price band by promoters and existing shareholders.
This aggregated the total issue size to Rs 1,952 crore.
The Pune-based company is engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
Read also: Emcure Pharma set to launch IPO on July 3
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.